NCT02646943

Brief Summary

BACKGROUND: Chagas Disease (ChD) remains as one of the most neglected diseases in the world, with 8-10 million infected people and only one marginally effective therapeutic. The lack of good biomarkers for active infection or clinical end-points poses a problem for assessing the performance of new drugs or therapeutic interventions. Among the biomarkers, several studies showed that Brain Natriuretic Peptide (NT-ProBNP) is accurate maker of left ventricular systolic and diastolic dysfunction. OBJECTIVE: Our long term goal is to establish The Sao Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) as a Center of Excellence for Neglected Infectious Disease Research in Brazil. The Specific Aims are to begin that process by focusing on Trypanosoma cruzi infection with the goal of finding an array of biomarkers that correlate with parasite persistence and Chagas cardiac disease status that can be used to infer risk of disease progression and death as well used as markers of cure (parasite eradication) or clinical efficacy (stabilize or reverse cardiac damage) of novel drugs METHOD: The investigators established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC). The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years (baseline and 24 months) . The evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,959

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2013

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2013

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

December 27, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 6, 2016

Completed
Last Updated

January 6, 2016

Status Verified

January 1, 2016

Enrollment Period

1 year

First QC Date

December 27, 2015

Last Update Submit

January 5, 2016

Conditions

Keywords

CohortBiomarkersCardiomyopathy

Outcome Measures

Primary Outcomes (1)

  • Death

    24 months

Secondary Outcomes (2)

  • Changes in the ECG pattern

    baseline and 24 months

  • Hospitalization due to cardiovascular

    baseline and 24 months

Study Arms (1)

Cohort of patients with chronic chagas cardiomyopathy

We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice. The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients will be selected based on the ECG results performed in 2011-12 by the Telehealth Network. Since the TeleHealth System is currently acting in support of the Primary Care system, these patients are under the care of primary care physicians of the Health Family Strategy, a public primary care program that has a high coverage in the state of Minas Gerais.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (43)

  • Harrell FE, Jr. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2001.

    BACKGROUND
  • Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development,Validation, and Updating. New York: Springer, 2009.

    BACKGROUND
  • Rassi A Jr, Rassi A. The art of risk stratification in Chagas' disease. J Cardiovasc Electrophysiol. 2008 Jun;19(6):E40; author reply E41. doi: 10.1111/j.1540-8167.2008.01172.x. Epub 2008 Apr 21. No abstract available.

    PMID: 18462337BACKGROUND
  • Nunes MC, Reis RC, Colosimo EA, Ribeiro AL, Barbosa FB, da Silva JL, Botoni FA, Barbosa MM, Rocha MO. Risk estimation approach in Chagas disease is still needed. Int J Cardiol. 2011 Mar 3;147(2):294-6. doi: 10.1016/j.ijcard.2010.12.044. Epub 2010 Dec 30. No abstract available.

    PMID: 21194765BACKGROUND
  • Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 2003 Jan 1;8:e44-54. doi: 10.2741/926.

  • Rocha MO, Teixeira MM, Ribeiro AL. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther. 2007 Aug;5(4):727-43. doi: 10.1586/14787210.5.4.727.

  • Lima-Costa MF, Peixoto SV, Ribeiro ALP. Chagas disease and mortality in old age as an emerging issue: 10 year follow-up of the Bambui population-based cohort study (Brazil). Int J Cardiol. 2010 Nov 19;145(2):362-363. doi: 10.1016/j.ijcard.2010.02.036.

  • Pereira Nunes Mdo C, Barbosa MM, Ribeiro AL, Amorim Fenelon LM, Rocha MO. Predictors of mortality in patients with dilated cardiomyopathy: relevance of chagas disease as an etiological factor. Rev Esp Cardiol. 2010 Jul;63(7):788-97. doi: 10.1016/s1885-5857(10)70163-8. English, Spanish.

  • Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007 Mar 6;115(9):1101-8. doi: 10.1161/CIRCULATIONAHA.106.627265.

  • Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, Rassi GG, Hasslocher-Moreno A, Sousa AS, Scanavacca MI. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006 Aug 24;355(8):799-808. doi: 10.1056/NEJMoa053241.

  • Rocha MO, Ribeiro AL. A risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006 Dec 7;355(23):2488-9; author reply 2490-1. doi: 10.1056/NEJMc062580. No abstract available.

  • Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995 Dec;48(12):1503-10. doi: 10.1016/0895-4356(95)00048-8.

  • Macfarlane PW, Latif S. Automated serial ECG comparison based on the Minnesota code. J Electrocardiol. 1996;29 Suppl:29-34. doi: 10.1016/s0022-0736(96)80016-1.

  • Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy--where do we stand after a hundred years? Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):300-16. doi: 10.1016/j.pcad.2009.11.008.

  • Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin Infect Dis. 2004 Apr 1;38(7):943-50. doi: 10.1086/381892. Epub 2004 Mar 10.

  • Ferreira RC, Ianni BM, Abel LC, Buck P, Mady C, Kalil J, Cunha-Neto E. Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/"indeterminate" and Chagas disease cardiomyopathy patients. Mem Inst Oswaldo Cruz. 2003 Apr;98(3):407-11. doi: 10.1590/s0074-02762003000300021. Epub 2003 Jul 18.

  • Lula JF, Rocha MO, Nunes Mdo C, Ribeiro AL, Teixeira MM, Bahia MT, Talvani A. Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction. Eur J Heart Fail. 2009 Sep;11(9):825-31. doi: 10.1093/eurjhf/hfp105. Epub 2009 Aug 4.

  • Ribeiro AL, Alkmim MB, Cardoso CS, Carvalho GG, Caiaffa WT, Andrade MV, Cunha DF, Antunes AP, Resende AG, Resende ES. Implementation of a telecardiology system in the state of Minas Gerais: the Minas Telecardio Project. Arq Bras Cardiol. 2010 Jul;95(1):70-8. doi: 10.1590/s0066-782x2010005000060. Epub 2010 Jun 11.

  • Cardoso CS, Bandeira M, Ribeiro AL, Oliveira GL, Caiaffa WT. [Satisfaction scales with health care to cardiovascular diseases: CARDIOSATIS--patient and team]. Cien Saude Colet. 2011;16 Suppl 1:1401-7. doi: 10.1590/s1413-81232011000700075. Portuguese.

  • Cardoso CS, Ribeiro AL, Castro RL, Cesar CC, Caiaffa WT. Implementation of a cardiology care program in remote areas in Brazil: influence of governability. Rural Remote Health. 2010 Jul-Sep;10(3):1472. Epub 2010 Sep 8.

  • Migowski A, Chaves RB, Coeli CM, Ribeiro AL, Tura BR, Kuschnir MC, Azevedo VM, Floriano DB, Magalhaes CA, Pinheiro MC, Xavier RM. Accuracy of probabilistic record linkage in the assessment of high-complexity cardiology procedures. Rev Saude Publica. 2011 Apr;45(2):269-75. doi: 10.1590/s0034-89102011005000012. Epub 2011 Feb 25.

  • BLACKBURN H, KEYS A, SIMONSON E, RAUTAHARJU P, PUNSAR S. The electrocardiogram in population studies. A classification system. Circulation. 1960 Jun;21:1160-75. doi: 10.1161/01.cir.21.6.1160. No abstract available.

  • Ribeiro AL, dos Reis AM, Barros MV, de Sousa MR, Rocha AL, Perez AA, Pereira JB, Machado FS, Rocha MO. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet. 2002 Aug 10;360(9331):461-2. doi: 10.1016/S0140-6736(02)09638-1.

  • Barbosa MM, Nunes Mdo C, Ribeiro AL, Barral MM, Rocha MO. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur J Echocardiogr. 2007 Jun;8(3):204-12. doi: 10.1016/j.euje.2006.03.011. Epub 2006 May 2.

  • Ribeiro AL, Reis AM, Teixeira MM, Rocha MO. Brain natriuretic peptide in Chagas' disease: further insights. Lancet. 2003 Jul 26;362(9380):333. doi: 10.1016/S0140-6736(03)13990-6. No abstract available.

  • Ribeiro AL, Teixeira MM, Reis AM, Talvani A, Perez AA, Barros MV, Rocha MO. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int J Cardiol. 2006 Apr 28;109(1):34-40. doi: 10.1016/j.ijcard.2005.05.048. Epub 2005 Jul 14.

  • Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos J, Ribeiro AL, Teixeira MM. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz. 2004 Oct;99(6):645-9. doi: 10.1590/s0074-02762004000600020. Epub 2004 Nov 18.

  • Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos J, Ribeiro AL, Teixeira MM. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int J Cardiol. 2005 Apr 28;100(3):503-4. doi: 10.1016/j.ijcard.2004.06.007. No abstract available.

  • Oliveira BM, Botoni FA, Ribeiro AL, Pinto AS, Reis AM, Nunes Mdo C, Rocha MO. Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle filling pressure in patients with Chagasic cardiomyopathy. Echocardiography. 2009 May;26(5):521-7. doi: 10.1111/j.1540-8175.2008.00842.x.

  • Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. Am J Epidemiol. 2010 Jul 15;172(2):190-6. doi: 10.1093/aje/kwq106. Epub 2010 Jun 25.

  • Lima-Costa MF, Matos DL, Ribeiro AL. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambui cohort study of aging. Stroke. 2010 Nov;41(11):2477-82. doi: 10.1161/STROKEAHA.110.588061. Epub 2010 Sep 23.

  • Ribeiro AL, Rocha MO. [Indeterminate form of Chagas disease: considerations about diagnosis and prognosis]. Rev Soc Bras Med Trop. 1998 May-Jun;31(3):301-14. doi: 10.1590/s0037-86821998000300008. Portuguese.

  • Maguire JH, Hoff R, Sherlock I, Guimaraes AC, Sleigh AC, Ramos NB, Mott KE, Weller TH. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation. 1987 Jun;75(6):1140-5. doi: 10.1161/01.cir.75.6.1140.

  • Ribeiro AL, Rocha MO, Barros MV, Rodrigues AR, Machado FS. A narrow QRS does not predict a normal left ventricular function in Chagas' disease. Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):2014-7. doi: 10.1111/j.1540-8159.2000.tb07076.x.

  • Nascimento BR, Araujo CG, Rocha MO, Domingues JD, Rodrigues AB, Barros MV, Ribeiro AL. The prognostic significance of electrocardiographic changes in Chagas disease. J Electrocardiol. 2012 Jan-Feb;45(1):43-8. doi: 10.1016/j.jelectrocard.2011.04.011. Epub 2011 Jun 24.

  • Ribeiro AL, Cavalvanti PS, Lombardi F, Nunes Mdo C, Barros MV, Rocha MO. Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol. 2008 May;19(5):502-9. doi: 10.1111/j.1540-8167.2007.01088.x. Epub 2008 Feb 4.

  • Ribeiro AL, Rocha MO, Terranova P, Cesarano M, Nunes MD, Lombardi F. T-wave amplitude variability and the risk of death in Chagas disease. J Cardiovasc Electrophysiol. 2011 Jul;22(7):799-805. doi: 10.1111/j.1540-8167.2010.02000.x. Epub 2011 Jan 14.

  • Nunes Mdo C, Rocha MO, Ribeiro AL, Colosimo EA, Rezende RA, Carmo GA, Barbosa MM. Right ventricular dysfunction is an independent predictor of survival in patients with dilated chronic Chagas' cardiomyopathy. Int J Cardiol. 2008 Jul 21;127(3):372-9. doi: 10.1016/j.ijcard.2007.06.012. Epub 2007 Aug 8.

  • Nunes MC, Barbosa MM, Ribeiro AL, Colosimo EA, Rocha MO. Left atrial volume provides independent prognostic value in patients with Chagas cardiomyopathy. J Am Soc Echocardiogr. 2009 Jan;22(1):82-8. doi: 10.1016/j.echo.2008.11.015.

  • Ferreira AM, Santos LI, Sabino EC, Ribeiro ALP, Oliveira-da Silva LC, Damasceno RF, D'Angelo MFSV, Nunes MDCP, Haikal DSA. Two-year death prediction models among patients with Chagas Disease using machine learning-based methods. PLoS Negl Trop Dis. 2022 Apr 14;16(4):e0010356. doi: 10.1371/journal.pntd.0010356. eCollection 2022 Apr.

  • Quintino ND, Sabino EC, da Silva JLP, Ribeiro ALP, Ferreira AM, Davi GL, Oliveira CDL, Cardoso CS. Factors associated with quality of life in patients with Chagas disease: SaMi-Trop project. PLoS Negl Trop Dis. 2020 May 27;14(5):e0008144. doi: 10.1371/journal.pntd.0008144. eCollection 2020 May.

  • Cardoso CS, Ribeiro ALP, Oliveira CDL, Oliveira LC, Ferreira AM, Bierrenbach AL, Silva JLP, Colosimo EA, Ferreira JE, Lee TH, Busch MP, Reingold AL, Sabino EC. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study. PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006814. doi: 10.1371/journal.pntd.0006814. eCollection 2018 Nov.

  • Cardoso CS, Sabino EC, Oliveira CD, de Oliveira LC, Ferreira AM, Cunha-Neto E, Bierrenbach AL, Ferreira JE, Haikal DS, Reingold AL, Ribeiro AL. Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. BMJ Open. 2016 May 4;6(5):e011181. doi: 10.1136/bmjopen-2016-011181.

MeSH Terms

Conditions

Chagas DiseaseCardiomyopathies

Condition Hierarchy (Ancestors)

TrypanosomiasisEuglenozoa InfectionsProtozoan InfectionsParasitic DiseasesInfectionsVector Borne DiseasesHeart DiseasesCardiovascular Diseases

Study Officials

  • Ester C Sabino, PhD

    University of Sao Paulo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 27, 2015

First Posted

January 6, 2016

Study Start

July 1, 2013

Primary Completion

July 1, 2014

Study Completion

August 1, 2014

Last Updated

January 6, 2016

Record last verified: 2016-01

Data Sharing

IPD Sharing
Will share

The Dataset will be open access for two years at the end of the data collection process (August, 2018). In the meantime, applications to use the data should be made by contacting the researchers of the SaMi-Trop cohort and filling up the application form. The questionnaires and interviewer guides of the baseline will also be available in electronic formats at http://www.ufsj.edu.br/tecnologiasemsaude\_pesquisa/projetos.php